Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Arcturus Therapeutics stock

Learn how to easily invest in Arcturus Therapeutics stock.

Arcturus Therapeutics Holdings Inc is a biotechnology business based in the US. Arcturus Therapeutics shares (ARCT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcturus Therapeutics employs 118 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Arcturus Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARCT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Arcturus Therapeutics stock price (NASDAQ: ARCT)

Use our graph to track the performance of ARCT stocks over time.

Arcturus Therapeutics shares at a glance

Information last updated 2022-01-18.
Latest market close$24.59
52-week range$24.87 - $89.18
50-day moving average $37.66
200-day moving average $39.57
Wall St. target price$85.45
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-7.56

Buy Arcturus Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arcturus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arcturus Therapeutics price performance over time

Historical closes compared with the close of $24.59 from 2022-01-21

1 week (2022-01-14) -26.55%
1 month (2021-12-22) -42.34%
3 months (2021-10-22) -44.75%
6 months (2021-07-22) -21.91%
1 year (2021-01-22) -63.68%
2 years (2020-01-22) 98.79%
3 years (2019-01-22) 397.78%
5 years (2017-01-20) 2,383.84%

Arcturus Therapeutics financials

Revenue TTM $8.8 million
Gross profit TTM $-48,307,000
Return on assets TTM -32.41%
Return on equity TTM -75.32%
Profit margin 0%
Book value $9.83
Market capitalisation $882.5 million

TTM: trailing 12 months

Arcturus Therapeutics share dividends

We're not expecting Arcturus Therapeutics to pay a dividend over the next 12 months.

Have Arcturus Therapeutics's shares ever split?

Arcturus Therapeutics's shares were split on a 1:7 basis on 15 November 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arcturus Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Arcturus Therapeutics shares which in turn could have impacted Arcturus Therapeutics's share price.

Arcturus Therapeutics share price volatility

Over the last 12 months, Arcturus Therapeutics's shares have ranged in value from as little as $24.87 up to $89.1809. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arcturus Therapeutics's is 2.631. This would suggest that Arcturus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Arcturus Therapeutics overview

Arcturus Therapeutics Holdings Inc. , an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Arcturus Therapeutics is owned by insiders or institutions?
Currently 13.907% of Arcturus Therapeutics shares are held by insiders and 70.056% by institutions.
How many people work for Arcturus Therapeutics?
Latest data suggests 118 work at Arcturus Therapeutics.
When does the fiscal year end for Arcturus Therapeutics?
Arcturus Therapeutics's fiscal year ends in December.
Where is Arcturus Therapeutics based?
Arcturus Therapeutics's address is: 10628 Science Center Drive, San Diego, CA, United States, 92121
What is Arcturus Therapeutics's ISIN number?
Arcturus Therapeutics's international securities identification number is: US03969T1097
What is Arcturus Therapeutics's CUSIP number?
Arcturus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03969T109

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site